Drug Profile

JWTCR 001

Alternative Names: JWTCR-001; TCR-MAGE-A4 T-Cells

Latest Information Update: 23 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MediGene AG
Developer JW Therapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I Solid tumours

Most Recent Events

14 Jan 2025 Medigene has patent protection for MAGE-A4-targeted TCR in Japan
05 Dec 2024 Medigene has patent protection for JWTCR 001 in China
06 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Recurrent, Metastatic disease, In adults, In the elderly) in China (Parenteral) (NCT06170294)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com